Table II.
Pearson's Correlation Coefficient of PSA, VEGF, PEDF and Ratio VEGF/PEDF serum in PCa, BPH and healthy groups.
| Serum | ||||
|---|---|---|---|---|
| Group | VEGF | PEDF | Ratio | |
| PCa | t-PSA | 0.458a | 0.389 | 0.316 |
| VEGF | – | 0.900c | 0.613b | |
| PEDF | – | – | 0.259 | |
| AdGS6-7 | t-PSA | −0.129 | 0.037 | −0.251 |
| VEGF | – | 0.775b | 0.695 | |
| PEDF | – | – | 0.112 | |
| AdGS8-10 | t-PSA | 0.460 | 0.426 | 0.314 |
| VEGF | – | 0.927b | 0.556 | |
| PEDF | – | – | 0.262 | |
| BPH | t-PSA | −0.300 | 0.077 | −0.578b |
| VEGF | – | 0.690b | 0.620b | |
| PEDF | – | – | −0.079 | |
| Healthy | t-PSA | −0.046 | −0.051 | −0.008 |
| VEGF | – | −.347 | −0.883c | |
| PEDF | – | – | −0.730c | |
a
P≤0.05
b
P<0.01
c
P<0.001. pCA, prostate cancer; BPH, benign prostatic hyperplasia; AdGSC, adenocarcinoma with Gleason score; VEGF, vascular endothelial growth factor; PEDF, pigment epithelium-derived factor; t-PSA, total-prostate-specific antigen.